Merck KGaA, Darmstadt (Germany), announced that the American Academy of Neurology (AAN) has accepted a late-breaking abstract regarding cladribine tablets, its oral investigational treatment of multiple sclerosis, for an oral presentation at the AAn 61 st Annual Meeting in Seattle.

The abstarct is entitled"Results from the Clarity-a-study: a phase III, randomized, double-blind study to evaluate the safety and efficacy of oral cladribine in relapsing-remitting multiple sclerosis". The data is currently scheduled to be presented as a late-breaking oral presentation on April 29.

Merck, headquartered in Darmstadt (Germany), is a global pharmaceutical and chemical enterprise with around 33.000 employees in 59 countries. Merck is the world`s oldest pharmaceutical and chemical company- its roots date back to 1668.

The pharmaceutical business sector comprises innovative prescription drugs as well as over-the -counter products. The chemicals business sector offers specialty products for the electronics, printing, coatings, cosmetics, pharmaceutical and biotech industries.

(Source: Company)